Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

Peripheral neuropathy is a common adverse effect of neurotoxic chemotherapy. In a randomized, double-blind clinical trial, an investigational hand therapy was not more effective at preventing ...

Figures in parentheses refer to results during the corresponding period of the previous yearThe Group's sales amounted to 64.8 (61.2) MSEK for the third quarter of the year.The Group's net result tota ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

Scientists have designed a groundbreaking painkiller that activates solely at chronic pain sites, offering targeted, ...

Artelo Biosciences ( (ARTL) ) has released its Q3 earnings. Here is a breakdown of the information Artelo Biosciences presented to its ...

Researchers have developed a non-addictive painkiller that remains inactive until it reaches sites of chronic pain. Instead of dulling the nerves that send the pain signals like other analgesics, this ...

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect for patients undergoing cancer treatments, and ...

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, ...

Gorgas, President and CEO of Artelo Biosciences. “Starting with ART26.12, our promising Fatty Acid Binding Protein 5 (FABP5) inhibitor drug candidate, we received FDA clearance to begin trials in ...

TRV045 reversed thermal hyperalgesia, a measure of neuropathic pain, in nonclinical models of diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy. TRV045 was not associated ...